These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 9383574)

  • 21. Potent and selective gene inhibition using antisense oligodeoxynucleotides.
    Flanagan WM; Wagner RW
    Mol Cell Biochem; 1997 Jul; 172(1-2):213-25. PubMed ID: 9278247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo.
    Riedel F; Götte K; Li M; Hörmann K; Grandis JR
    Int J Oncol; 2003 Sep; 23(3):577-83. PubMed ID: 12888890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specific block of androgen receptor activity by antisense oligonucleotides.
    Hamy F; Brondani V; Spoerri R; Rigo S; Stamm C; Klimkait T
    Prostate Cancer Prostatic Dis; 2003; 6(1):27-33. PubMed ID: 12664061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antisense oligonucleotide inhibition of coxsackievirus B3 gene expression in HeLa cells and dose-response experiments].
    Liu ZW; Sun HM; Xiao ZH; Qiu N; Zhang T; Zhao JM
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Mar; 18(1):62-5. PubMed ID: 15340530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides.
    Detrick B; Nagineni CN; Grillone LR; Anderson KP; Henry SP; Hooks JJ
    Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):163-9. PubMed ID: 11133862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antisense oligonucleotides: a new therapeutic approach].
    Guinot P; Temsamani J
    Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nuclear location of synthetic oligonucleotides microinjected somatic cells: its implication in an antisense strategy.
    Mechti N; Leonetti JP; Clarenc JP; Degols G; Lebleu B
    Nucleic Acids Symp Ser; 1991; (24):147-50. PubMed ID: 1668686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA.
    Lewis JG; Lin KY; Kothavale A; Flanagan WM; Matteucci MD; DePrince RB; Mook RA; Hendren RW; Wagner RW
    Proc Natl Acad Sci U S A; 1996 Apr; 93(8):3176-81. PubMed ID: 8622909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of transforming growth factor beta (TGFbeta1) expression and extracellular matrix secretion in human peritoneal mesothelial cells by pcDU6 vector-mediated TGFbeta1 shRNA and by pcDNA3.1(-)-mediated antisense TGFbeta1 RNA.
    Liu F; Liu H; Peng Y; Yuan F; Liu Y; Duan S
    Adv Perit Dial; 2005; 21():41-52. PubMed ID: 16686283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect on HLA-I expression in the presence of antisense oligonucleotides complementary to hepatitis B virus x gene].
    Feng Z; Zhou Y; Yao Z
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1998 Dec; 12(4):313-5. PubMed ID: 12526341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli.
    Deere J; Iversen P; Geller BL
    Antimicrob Agents Chemother; 2005 Jan; 49(1):249-55. PubMed ID: 15616302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The high binding affinity of phosphorothioate-modified oligomers for Ff gene 5 protein is moderated by the addition of C-5 propyne or 2'-O-methyl modifications.
    Mou TC; Gray DM
    Nucleic Acids Res; 2002 Feb; 30(3):749-58. PubMed ID: 11809888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of oligonucleotide length, mismatches and mRNA levels on C-5 propyne-modified antisense potency.
    Flanagan WM; Kothavale A; Wagner RW
    Nucleic Acids Res; 1996 Aug; 24(15):2936-41. PubMed ID: 8760877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Towards genomic drug therapy with antisense oligonucleotides.
    Lönnberg H; Vuorio E
    Ann Med; 1996 Dec; 28(6):511-22. PubMed ID: 9017110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo.
    Bertrand JR; Pottier M; Vekris A; Opolon P; Maksimenko A; Malvy C
    Biochem Biophys Res Commun; 2002 Aug; 296(4):1000-4. PubMed ID: 12200148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antisense therapeutics: from theory to clinical practice.
    Pirollo KF; Rait A; Sleer LS; Chang EH
    Pharmacol Ther; 2003 Jul; 99(1):55-77. PubMed ID: 12804699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elucidating cell signaling mechanisms using antisense technology.
    Koller E; Gaarde WA; Monia BP
    Trends Pharmacol Sci; 2000 Apr; 21(4):142-8. PubMed ID: 10740290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of gene expression by anti-sense oligodeoxynucleotides.
    Zheng RQ; Kemeny DM
    Clin Exp Immunol; 1995 Jun; 100(3):380-2. PubMed ID: 7774046
    [No Abstract]   [Full Text] [Related]  

  • 39. The state of the art in antisense research.
    Wagner RW
    Nat Med; 1995 Nov; 1(11):1116-8. PubMed ID: 7584973
    [No Abstract]   [Full Text] [Related]  

  • 40. Structure-activity relationships in cell culture.
    Wagner RW
    Ciba Found Symp; 1997; 209():142-54; discussion 154-7. PubMed ID: 9383574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.